Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions
AXSM Stock Forecast
Axsome Therapeutics stock forecast is as follows: an average price target of $117.83 (represents a 35.05% upside from AXSM’s last price of $87.25) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
AXSM Price Target
The average price target for Axsome Therapeutics (AXSM) is $117.83 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $80.00. This represents a potential 35.05% upside from AXSM's last price of $87.25.
AXSM Analyst Ratings
According to 14 Wall Street analysts, Axsome Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AXSM stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 1 'Hold' (7.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Axsome Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Graig Suvannavejh | Mizuho Securities | $106.00 | $90.58 | 17.03% | 21.49% |
| Sep 03, 2024 | Cerena Chen | Wells Fargo | $140.00 | $88.86 | 57.55% | 60.46% |
| Aug 06, 2024 | Raghuram Selvaraju | H.C. Wainwright | $180.00 | $83.21 | 116.32% | 106.30% |
| Aug 06, 2024 | Jason Gerberry | Bank of America Securities | $106.00 | $83.93 | 26.30% | 21.49% |
| Jul 22, 2024 | Leonid Timashev | RBC Capital | $131.00 | $84.85 | 54.39% | 50.14% |
| Jun 05, 2024 | Leonid Timashev | RBC Capital | $130.00 | $72.24 | 79.96% | 49.00% |
| May 28, 2024 | David Amsellem | Piper Sandler | $115.00 | $75.19 | 52.95% | 31.81% |
| Apr 29, 2024 | Vikram Purohit | Morgan Stanley | $115.00 | $74.14 | 55.11% | 31.81% |
| Mar 28, 2024 | Graig Suvannavejh | Mizuho Securities | $109.00 | $79.17 | 37.68% | 24.93% |
| Mar 18, 2024 | Joel Beatty | Robert W. Baird | $108.00 | $72.54 | 48.88% | 23.78% |
The latest Axsome Therapeutics stock forecast, released on Sep 11, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $106.00, which represents a 17.03% increase from the stock price at the time of the forecast ($90.58), and a 21.49% increase from AXSM last price ($87.25).
Axsome Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 10 |
| Avg Price Target | - | $133.00 | $124.00 |
| Last Closing Price | $87.25 | $87.25 | $87.25 |
| Upside/Downside | -100.00% | 52.44% | 42.12% |
In the current month, the average price target of Axsome Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Axsome Therapeutics's last price of $87.25. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Oct 04, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 09, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Wells Fargo | Buy | Overweight | Initialise |
| Aug 23, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 22, 2024 | UBS | Buy | Buy | Hold |
| Aug 22, 2024 | RBC Capital | Underperform | Underperform | Hold |
Axsome Therapeutics's last stock rating was published by Wells Fargo on Oct 04, 2024. The company gave AXSM a "Buy" rating, the same as its previous rate.
Axsome Therapeutics Financial Forecast
Axsome Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $57.79M | $46.70M | $94.58M | $24.37M | $16.85M | $8.82M |
| Avg Forecast | $383.21M | $330.84M | $280.26M | $213.88M | $201.06M | $158.22M | $135.07M | $115.39M | $112.92M | $98.37M | $86.92M | $73.29M | $69.24M | $54.87M | $40.88M | $25.47M | $21.75M | $16.64M | $6.92M |
| High Forecast | $383.21M | $330.84M | $280.26M | $213.88M | $201.06M | $158.22M | $135.07M | $115.39M | $112.92M | $104.03M | $86.92M | $73.29M | $70.60M | $60.04M | $40.88M | $25.47M | $21.75M | $16.64M | $6.92M |
| Low Forecast | $383.21M | $330.84M | $280.26M | $213.88M | $201.06M | $158.22M | $135.07M | $115.39M | $112.92M | $93.58M | $86.92M | $73.29M | $66.51M | $48.88M | $40.88M | $25.47M | $21.75M | $16.64M | $6.92M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.14% | 3.71% | 1.12% | 1.01% | 1.27% |
Axsome Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $69.24M, with a low forecast of $66.51M, and a high forecast of $70.60M. AXSM's average Quarter revenue forecast represents a 19.81% increase compared to the company's last Quarter revenue of $57.79M (Sep 23).
Axsome Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-62.12M | $-65.06M | $-4.96M | $-53.70M | $-40.49M | $-38.77M |
| Avg Forecast | $103.42M | $89.28M | $75.63M | $57.72M | $54.26M | $42.70M | $36.45M | $31.14M | $30.47M | $26.55M | $23.46M | $19.78M | $18.69M | $14.81M | $11.03M | $6.87M | $5.87M | $4.49M | $1.87M |
| High Forecast | $103.42M | $89.28M | $75.63M | $57.72M | $54.26M | $42.70M | $36.45M | $31.14M | $30.47M | $28.07M | $23.46M | $19.78M | $19.05M | $16.20M | $11.03M | $6.87M | $5.87M | $4.49M | $1.87M |
| Low Forecast | $103.42M | $89.28M | $75.63M | $57.72M | $54.26M | $42.70M | $36.45M | $31.14M | $30.47M | $25.25M | $23.46M | $19.78M | $17.95M | $13.19M | $11.03M | $6.87M | $5.87M | $4.49M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.20% | -5.90% | -0.72% | -9.15% | -9.02% | -20.77% |
undefined analysts predict AXSM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Axsome Therapeutics's previous annual EBITDA (undefined) of $NaN.
Axsome Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-62.20M | $-67.17M | $-11.22M | $-66.76M | $-47.23M | $-42.84M |
| Avg Forecast | $122.06M | $87.59M | $54.59M | $12.48M | $8.43M | $-18.85M | $-36.24M | $-50.07M | $-54.19M | $-65.82M | $-62.19M | $-57.30M | $-55.73M | $-57.24M | $-57.73M | $-62.03M | $-53.56M | $-49.96M | $-47.86M |
| High Forecast | $122.06M | $87.59M | $54.59M | $12.48M | $8.43M | $-18.85M | $-36.24M | $-50.07M | $-54.19M | $-44.83M | $-62.19M | $-57.30M | $-49.74M | $-44.74M | $-57.73M | $-62.03M | $-53.56M | $-49.96M | $-47.86M |
| Low Forecast | $122.06M | $87.59M | $54.59M | $12.48M | $8.43M | $-18.85M | $-36.24M | $-50.07M | $-54.19M | $-75.83M | $-62.19M | $-57.30M | $-67.24M | $-63.98M | $-57.73M | $-62.03M | $-53.56M | $-49.96M | $-47.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.16% | 0.18% | 1.25% | 0.95% | 0.89% |
Axsome Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AXSM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Axsome Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.19M | $78.94M | $74.19M | $61.50M | $40.89M | $31.16M |
| Avg Forecast | $565.37M | $488.11M | $413.48M | $315.55M | $296.64M | $233.44M | $199.28M | $170.24M | $166.60M | $145.13M | $128.24M | $108.13M | $102.16M | $80.95M | $60.31M | $37.58M | $32.09M | $24.54M | $10.21M |
| High Forecast | $565.37M | $488.11M | $413.48M | $315.55M | $296.64M | $233.44M | $199.28M | $170.24M | $166.60M | $153.48M | $128.24M | $108.13M | $104.16M | $88.57M | $60.31M | $37.58M | $32.09M | $24.54M | $10.21M |
| Low Forecast | $565.37M | $488.11M | $413.48M | $315.55M | $296.64M | $233.44M | $199.28M | $170.24M | $166.60M | $138.06M | $128.24M | $108.13M | $98.12M | $72.12M | $60.31M | $37.58M | $32.09M | $24.54M | $10.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.31% | 1.97% | 1.92% | 1.67% | 3.05% |
Axsome Therapeutics's average Quarter SG&A projection for Dec 23 is $102.16M, based on 7 Wall Street analysts, with a range of $98.12M to $104.16M. The forecast indicates a 22.80% rise compared to AXSM last annual SG&A of $83.19M (Sep 23).
Axsome Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 7 | 10 | 9 | 9 | 8 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.32 | $-0.00 | $-0.26 | $-1.54 | $-1.13 | $-1.10 |
| Avg Forecast | $2.57 | $1.84 | $1.15 | $0.26 | $0.18 | $-0.40 | $-0.76 | $-1.05 | $-1.14 | $-1.38 | $-1.31 | $-1.20 | $-1.17 | $-1.20 | $-1.21 | $-1.30 | $-1.13 | $-1.05 | $-1.01 |
| High Forecast | $2.57 | $1.84 | $1.15 | $0.26 | $0.18 | $-0.40 | $-0.76 | $-1.05 | $-1.14 | $-0.94 | $-1.31 | $-1.20 | $-1.05 | $-0.94 | $-1.21 | $-1.30 | $-1.13 | $-1.05 | $-1.01 |
| Low Forecast | $2.57 | $1.84 | $1.15 | $0.26 | $0.18 | $-0.40 | $-0.76 | $-1.05 | $-1.14 | $-1.59 | $-1.31 | $-1.20 | $-1.41 | $-1.34 | $-1.21 | $-1.30 | $-1.13 | $-1.05 | $-1.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.00% | 0.20% | 1.37% | 1.08% | 1.09% |
According to undefined Wall Street analysts, Axsome Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AXSM previous annual EPS of $NaN (undefined).
Axsome Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| ACAD | ACADIA Pharmaceuticals | $14.62 | $26.57 | 81.74% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| SRPT | Sarepta Therapeutics | $123.07 | $169.63 | 37.83% | Buy |
| AXSM | Axsome Therapeutics | $87.25 | $117.83 | 35.05% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| INCY | Incyte | $75.75 | $84.56 | 11.63% | Buy |
| TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
AXSM Forecast FAQ
Is Axsome Therapeutics a good buy?
Yes, according to 14 Wall Street analysts, Axsome Therapeutics (AXSM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of AXSM's total ratings.
What is AXSM's price target?
Axsome Therapeutics (AXSM) average price target is $117.83 with a range of $80 to $180, implying a 35.05% from its last price of $87.25. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Axsome Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AXSM stock, the company can go up by 35.05% (from the last price of $87.25 to the average price target of $117.83), up by 106.30% based on the highest stock price target, and down by -8.31% based on the lowest stock price target.
Can Axsome Therapeutics stock reach $130?
AXSM's highest twelve months analyst stock price target of $180 supports the claim that Axsome Therapeutics can reach $130 in the near future.
What are Axsome Therapeutics's analysts' financial forecasts?
Axsome Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $609.74M (high $609.74M, low $609.74M), average EBITDA is $164.55M (high $164.55M, low $164.55M), average net income is $-96.734M (high $-96.734M, low $-96.734M), average SG&A $899.59M (high $899.59M, low $899.59M), and average EPS is $-2.033 (high $-2.033, low $-2.033). AXSM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.21B (high $1.21B, low $1.21B), average EBITDA is $326.05M (high $326.05M, low $326.05M), average net income is $276.72M (high $276.72M, low $276.72M), average SG&A $1.78B (high $1.78B, low $1.78B), and average EPS is $5.82 (high $5.82, low $5.82).
Did the AXSM's actual financial results beat the analysts' financial forecasts?
Based on Axsome Therapeutics's last annual report (Dec 2022), the company's revenue was $50.04M, beating the average analysts forecast of $45.31M by 10.44%. Apple's EBITDA was $-171M, missing the average prediction of $12.23M by -1498.01%. The company's net income was $-198M, beating the average estimation of $-151M by 30.64%. Apple's SG&A was $159.25M, beating the average forecast of $66.85M by 138.24%. Lastly, the company's EPS was $-4.86, beating the average prediction of $-3.182 by 52.73%. In terms of the last quarterly report (Sep 2023), Axsome Therapeutics's revenue was $57.79M, beating the average analysts' forecast of $54.87M by 5.33%. The company's EBITDA was $-62.12M, missing the average prediction of $14.81M by -519.53%. Axsome Therapeutics's net income was $-62.199M, beating the average estimation of $-57.244M by 8.66%. The company's SG&A was $83.19M, beating the average forecast of $80.95M by 2.76%. Lastly, the company's EPS was $-1.32, beating the average prediction of $-1.203 by 9.70%